Analyst Price Targets — VERA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 11:51 am | — | Wedbush | $43.00 | $42.96 | TheFly | Vera Therapeutics price target raised to $43 from $35 at Wedbush |
| July 8, 2026 10:50 am | Vamil Divan | Guggenheim | $76.00 | $42.96 | StreetInsider | Vera Therapeutics (VERA) PT Raised to $76 at Guggenheim |
| July 8, 2026 10:42 am | — | Needham | $125.00 | $42.96 | StreetInsider | Vera Therapeutics (VERA) PT Raised to $125 at H.C. Wainwright |
| July 8, 2026 10:27 am | — | H.C. Wainwright | $125.00 | $42.96 | TheFly | Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright |
| June 2, 2026 7:56 pm | Farzin Haque | Jefferies | $60.00 | $31.26 | StreetInsider | Jefferies Reiterates Buy Rating on Vera Therapeutics (VERA) |
| June 2, 2026 3:15 pm | Paul Choi | Goldman Sachs | $90.00 | $32.14 | StreetInsider | Goldman Sachs on Vera Therapeutics (VERA): 'We are encouraged by today's update' |
| May 15, 2026 12:25 pm | — | Evercore ISI | $91.00 | $38.54 | TheFly | Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI |
| December 19, 2025 12:20 pm | — | Goldman Sachs | $95.00 | $47.69 | TheFly | Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs |
| December 11, 2025 1:21 pm | Laura Chico | Wedbush | $33.00 | $45.42 | TheFly | Vera Therapeutics price target raised to $33 from $23 at Wedbush |
| December 8, 2025 1:34 pm | Gavin Clark-Gartner | Evercore ISI | $97.00 | $45.79 | TheFly | Vera Therapeutics price target raised to $97 from $75 at Evercore ISI |
Latest News for VERA
Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression.
BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A…
BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
The U.S. Food and Drug Administration has approved Vera Therapeutics' drug to treat patients with a potentially life-threatening kidney disease, the regulator said on Tuesday, sending its shares up 6.2% in afternoon trading.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VERA.
U.S. House Trading
No House trades found for VERA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.